IFN-α Recombinant Protein Empowers Antiviral and Immunomodulatory Research

Author: Senior Product Manager of UA Views：9

IFN-α belongs to the type I interferon family and is produced by leukocytes and other immune-related cells upon stimulation by viruses, bacteria, or double-stranded RNA. It includes multiple subtypes and has functions such as antiviral activity, immune regulation, enhancement of antigen presentation, and activation of antitumor immunity.

Recent Advances
Product Information

Recent Advances

IFN‑α Recombinant Protein Empowers Antiviral and Immunomodulatory Research

Brief Introduction: IFN‑α belongs to the type I interferon family and is produced by immune-related cells such as leukocytes upon stimulation by viruses, bacteria, or double-stranded RNA. It comprises multiple subtypes and possesses functions including antiviral activity, immunomodulation, enhancement of antigen presentation, and activation of antitumor immunity. IFN‑α recombinant protein can be used for research on receptor binding, signaling pathways, immune cell function, antiviral mechanisms, and biopharmaceutical evaluation, making it an important tool in immunology, infectious disease, and tumor immunology research.

I. IFN‑α Is a Core Member of the Type I Interferon Family.

IFN‑α belongs to type I interferons and is mainly produced by leukocytes, plasmacytoid dendritic cells, and some stromal cells upon viral infection, bacterial stimulation, or double-stranded RNA recognition. The human IFN‑α gene family contains multiple subtypes, and different subtypes differ in amino acid sequence, receptor affinity, signal strength, and biological activity. IFN‑α and IFN‑β share the IFNAR1/IFNAR2 receptor complex, but they are not entirely identical in tissue distribution, induction conditions, and functional emphasis. IFN‑β is a single gene product, and its intramolecular disulfide bonds play an important role in maintaining spatial conformation and biological activity; IFN‑α is composed of multiple subtypes, with a molecular weight range of approximately 19‑26 kDa, exhibiting more complex subtype-specific regulatory characteristics.

II. IFN‑α Induces Cellular Antiviral State Through the JAK‑STAT Pathway.

Upon binding to IFNAR1/IFNAR2, IFN‑α activates JAK1 and TYK2, which in turn phosphorylate STAT1 and STAT2. Phosphorylated STAT1/STAT2 forms the ISGF3 complex with IRF9, translocates into the nucleus, and binds to interferon-stimulated response elements, inducing the expression of a large number of interferon-stimulated genes. These genes participate in inhibiting viral replication, limiting viral protein translation, degrading viral nucleic acids, enhancing antigen presentation, and regulating immune cell function. Therefore, IFN‑α not only directly restricts the viral life cycle but also establishes a broad-spectrum antiviral environment by remodeling the cellular transcriptional state.

III. IFN‑α Inhibits Viral Replication and Spread Through Multiple Pathways.

IFN‑α can inhibit viral protein synthesis via the PKR pathway. After PKR is activated by viral double-stranded RNA, it phosphorylates the translation initiation factor eIF‑2α, blocking viral mRNA translation. IFN‑α can also, through the 2'‑5' oligoadenylate synthetase pathway, convert ATP into oligoadenylates, activating RNase L and other endonucleases to degrade viral RNA. In addition, IFN‑α can affect viral adsorption, uncoating, nucleic acid transcription, assembly, and release. Different viruses exhibit varying sensitivities to IFN‑α and IFN‑β; for example, IFN‑α has a stronger inhibitory effect on hemorrhagic fever with renal syndrome virus, while IFN‑β may perform better in inhibiting transcription of certain viruses, suggesting functional division of labor among type I interferon subtypes.

IV. IFN‑α Has Significant Immunomodulatory and Antigen Presentation-Enhancing Effects.

IFN‑α can promote dendritic cell maturation and activation, enhancing their antigen presentation capacity. It can also upregulate MHC class I molecule expression, enhancing the recognition of infected or tumor cells by cytotoxic T cells; in some immune cells, it can also affect MHC class II molecule expression, thereby regulating adaptive immune responses. IFN‑α can activate NK cells and macrophages, enhancing ADCC effects and phagocytic clearance capacity, and promoting the elimination of virus-infected cells. These functions make IFN‑α an important cytokine connecting innate and adaptive immunity.

V. IFN‑α 2 Subtypes Hold an Important Position in Antiviral and Antitumor Applications.

The human IFN‑α 2 family includes variants such as IFN‑α2a, IFN‑α2b, and IFN‑α2c, with differences mainly located at key nucleotide positions in the coding region, such as amino acid changes related to positions 137 and 170. Among them, IFN‑α2a is one of the more extensively studied and clinically applied subtypes, commonly used in antiviral therapy and tumor immunomodulation research. Different IFN‑α subtypes may differ in receptor binding, half-life, glycosylation status, immunogenicity, and biological activity; therefore, recombinant expression, quality control, and functional evaluation need to be validated in the context of specific subtypes.

VI. IFN‑α Recombinant Protein Is an Important Reagent for Receptor Binding and Signaling Pathway Research.

IFN‑α recombinant protein can be used for IFNAR1/IFNAR2 binding experiments, receptor affinity determination, JAK‑STAT pathway activation detection, interferon-stimulated gene expression analysis, establishment of cellular antiviral state, immune cell function evaluation, and construction of positive control systems. Due to the numerous IFN‑α subtypes, selecting recombinant proteins with well-defined sequences, stable activity, and batch-to-batch consistency helps improve the reproducibility of receptor interaction research and functional validation, and provides a reliable foundation for downstream antibody screening, drug evaluation, and mechanistic studies.

Conclusion

In the research and development of antiviral drugs, immunomodulators, interferon analogs, and biosimilars, IFN‑α recombinant protein can be used for candidate molecule activity screening, neutralizing antibody evaluation, receptor occupancy detection, potency assay method development, comparability studies, and quality control validation. Meanwhile, IFN‑α recombinant protein can also be used in research on dendritic cell activation, NK cell function, MHC molecule expression, macrophage polarization, and tumor immune microenvironment regulation, providing upstream tool support for infectious immunity and tumor immunology translational research.

Addressing the research needs around the IFN‑α target and recombinant protein applications, UniAI provides IFN‑α 2a Protein, Human. This product is suitable for IFN‑α receptor binding analysis, JAK‑STAT signaling pathway research, antiviral function evaluation, immune cell activation experiments, antibody neutralizing activity detection, biosimilar comparability studies, and cytokine function validation. By providing stable and reliable recombinant protein tools, UniAI can offer technical support for IFN‑α-related basic and translational research.

IFN‑α recombinant protein is becoming an important tool connecting innate immunity, antiviral defense, and tumor immunomodulation research. With further elucidation of IFN‑α subtype functions, receptor selectivity, and downstream signaling networks, high-quality IFN‑α recombinant protein will play an even more important role in infectious disease mechanism research, immunotherapy evaluation, and biopharmaceutical development.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next